PFE logo
Pfizer Inc.
PFE
27.16 (0.30%) 0.08
Health Care
Pharmaceuticals
Pfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas including cardiovascular and migraine under the Eliquis Nurtec ODT/Vydura Zavzpret and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and COVID-19 prevention and treatment and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz Enbrel Inflectra Litfulo Velsipity and Cibinqo brands; amyloidosis hemophilia endocrine diseases and sickle cell disease under the Vyndaqel family Oxbryta BeneFIX Somavert Ngenla and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon Medrol Zavicefta Zithromax Octagam and Panzyga brands; and biologics small molecules immunotherapies and biosimilars under the Ibrance Xtandi Padcev Adcetris Inlyta Lorbrena Bosulif Tukysa Braftovi Mektovi Orgovyx Elrexfio Tivdak and Talzenna brands. In addition the company involved in the contract manufacturing business. It serves wholesalers retailers hospitals clinics government agencies pharmacies individual provider offices retail pharmacies and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. has strategic collaboration with Boltz PBC to develop and deploy state-of-the-art biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.

Quality Checklist 3/8

Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
5Y Shares Out Change < 0%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $154.42(B)
EV: $197.58(B)
Total Equity: $93.10(B)
Earnings date: Apr-28-2026
P/E: 19.82
Forward P/E: 9.18
P/FCF: 14.92
P/S: 2.47
P/B: 1.66
EPS: $1.4
EPS (fwd): $3.0
FCF/share: $1.8
Revenue/share: $11.0
Book value/share: $16.3
ROIC: 6.3%
ROA: 4.6%
ROE: 10.6%
Debt/Equity: 0.67
Current Ratio: 1.30
Gross margin: 75.8%
Operating margin: 24.6%
Net margin: 12.4%
Dividend/share: $1.7
Div. yield: 6.33%

PFE Valuation & Price Targets

Current Price
$27.2

Favorite Valuation Methods

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

64% undervalued
Low
$33.3
Mid
$44.4
High
$55.5
Current price
$27.2
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+12.83.03.226
FY+22.52.83.025
FY+32.02.42.916
FY+41.72.12.710
FY+51.52.12.910

Analyst Price Targets

1% overvalued
Low
$25.0
Mid
$27.0
High
$35.5
Current price
$27.2

Analyst Recommendations

Strong Buy2
Buy7
Hold16
Sell1
Strong Sell1

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate